| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Rogoff Medical Research Institute (A.R., R.N., A. N), and Metabolic Diseases Unit (R.K., R.N., C.R., U.A.L.), Beilinson Medical Center Petah Tikva
the Sackler School of Medicine, Tel-Aviv University Tel-Aviv, Israel
Address requests for reprints to: Dr. A. Ravid, Rogoff Medical Research Institute, Beilinson Medical Center, Petah Tikva 49100, Israel.
1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], like the immune response modulators prostaglandin E2 (PGE2) and histamine, inhibits mitogen-induced proliferation of human peripheral blood mononuclear cells. 1,25-(OH)2D3 acts synergistically with PGE2 and histamine to inhibit lymphocyte mitogenesis. This is apparent at a wide concentration range of 1,25-(OH)2D3 (3 x 10–11–10–8 mol/L). Cholera toxin, forskolin, and isobutylmethylxanthine, which like PGE2 and histamine increase intracellular concentrations of cAMP, also act synergistically with 1,25-(OH)2D3 in this system. Culture of mitogenstimulated adherent cell-depleted mononuclear cells with PGE2 increases the number of high affinity binding sites for 1,25-(OH)2D3. This finding may account for the synergistic interaction between the two agents.
* Presented in part at the Annual Meeting of the Society of Bone and Mineral Research, June 1987, and at the Seventh Workshop on Vitamin D, 1988. This work was supported by Grant 85–00276 from the U.S.-Israel Binational Science Foundation, Jerusalem, Israel.
Received September 5, 1989.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |